Bacillus Clausii

ApprovedSmall molecule

Sanofi

Bacillus Clausii is one of 79 small molecule programs targeting Acute Diarrhea. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute DiarrheaActive, not recruiting

Irritable Bowel SyndromeActive, not recruiting

GrowthActive, not recruiting

Acute DiarrheaApproved

Active, not recruiting

Irritable Bowel SyndromePhase 2/Phase 3

Active, not recruiting

GrowthApproved

Active, not recruiting

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

Bacillus Clausii

Sanofi

Approved

1 2

Genotropin

EMD Serono

Preclinical

35 3

Lovenox

Sanofi

Preclinical

2 4

Lenvima

Eisai

Preclinical

1 5

Zolymbus

AbbVie

Preclinical

1 6

Aricept

Eisai

Preclinical

1 7

Herceptin

OOrganon and Co

Preclinical

4 8

Somavaratan

Glucophage

2 10

EGRIFTA WR

TTheratechnologies

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diarrhea3 trials

ENterogermina® (Bacillus Clausii) In the manaGeMent of diarrheA in Children

Completed· Sanofi logo

Sanofi·Phase 3·NCT00457353·264 enrolled

Preventing Antibiotic-Associated DiarRhea Using Erceflora

Completed· Sanofi logo

Sanofi·Phase 4·NCT00447161·323 enrolled

Comparison of Effectiveness of Zinc Supplementation With ORS and Bacillus Clausii Versus Zinc With ORS and Saccharomyces Boulardii in Acute Watery Diarrhea in Paediatric Patients

Completed·RRESnTEC, Institute of Research·N/A·NCT06540209·60 enrolled

Growth1 trial

EFESO - EFficacy Enterogermina Small Intestinal Bacterial Overgrowth

Completed· Sanofi logo

Sanofi·Phase 4·NCT00331994·250 enrolled

Acute Diarrhea1 trial

Evaluation Of Bacillus Clausii In Treatment Of Acute Diarrhea In Latin American Children

Completed· Sanofi logo

Sanofi·Phase 4·NCT02169817·629 enrolled

Irritable Bowel Syndrome1 trial

Impact of Bacillus Clausii Administration on Irritable Bowel Syndrome Patients

Completed·HHospital Britanico·Phase 2/3·NCT03359499·80 enrolled

Antibiotic1 trial

DIAMANTE - Diseases Infectious Analysis Microflora Antibiotic Effect

Completed· Sanofi logo

Sanofi·Phase 4·NCT00424905·60 enrolled

1 more indication

Critically Ill Patients1 trial

Effect of Use of Probiotics on Systemic Infection in Critically Ill Patients: a Double Blind, Randomized, Placebo-controlled Trial

Enrolling by invitation·—·N/A·NCT07164781·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Bacillus Clausii. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bacillus Clausii compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bacillus Clausii. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Sanofi

Bacillus Clausii

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Diarrhea3 trials

Growth1 trial

Acute Diarrhea1 trial

Irritable Bowel Syndrome1 trial

Antibiotic1 trial

Critically Ill Patients1 trial

References

Drug Info

Quick Facts

Related News